Showing 8221-8230 of 8647 results for "".
- Novaliq and BLP Management Group Establish New Company, Betaliq, to Leverage EyeSol Technology to Treat Glaucomahttps://modernod.com/news/novaliq-and-blp-management-group-establish-new-company-betaliq-to-leverage-eyesol-technology-to-treat-glaucoma/2476500/Novaliq and BLP Management group announced the formation and funding of Betaliq. The Tampa-based company’s pipeline consists of two preservative-free glaucoma drug candidates based on new in class and best in class ß-blocker molecules using Novaliq’s waterfree EyeSol technology. Two EyeSol-
- Full Phase 2 Results Published Showing Efficacy, Safety, & Durability of Faricimab in DMEhttps://modernod.com/news/full-phase-2-results-published-showing-efficacy-safety-durability-of-faricimab-in-diabetic-macular-edema/2476497/Full results from Roche and Genentech’s phase 2 BOULEVARD study have been published in the journal, Ophthalmology. The study shows the investigational molecule, faricimab, was superior to ranibizumab in achieving
- Ziemer USA Sponsors NIIOS USA Cornea Eveninghttps://modernod.com/news/ziemer-usa-sponsors-niios-usa-cornea-evening-2/2476495/Ziemer USA is sponsoring the Netherlands Institute for Innovative Ocular Surgery (NIIOS) Cornea Evening in San Diego, California, on Friday, May 3, 2019, from 6-11 pm. For the third year in a row, NIIOS USA is organizing a Cornea Evening preceding the Annual Meeting of the American Society
- First Clinical Program Initiated Using Nanoparticles to Treat Retinitis Pigmentosahttps://modernod.com/news/first-clinical-program-initiated-using-nanoparticles-to-treat-retinitis-pigmentosa/2476490/2Ctech announced the initiation of the first-known clinical program to demonstrate the effectiveness and safety of Quantum Dots (QDs) to achieve photovoltaic stimulation of the neural retina for preservation or enhancement of vision in patients with retinal degenerative diseases and, in particula
- Older Drivers in UK Are Being Forced Off the Road as the NHS Rations Cataract Operations, Campaigners Warnhttps://modernod.com/news/older-drivers-in-uk-are-being-forced-off-the-road-as-the-nhs-rations-cataract-operations-campaigners-warn/2476481/Older drivers in the UK are being forced off the road by NHS cost-cutting that has resulted in the rationing of cataract treatment, according to a
- GenSight Biologics Reports Positive Follow-Up Results of Phase 3 Trial in LHONhttps://modernod.com/news/gensight-biologics-reports-positive-follow-up-results-of-phase-3-trial-in-lhon/2476475/GenSight Biologics announced results from the second scheduled readout, at week 72, of the RESCUE phase 3 clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 39 subjects whose visual loss due to 11778-ND4 Leber Hereditar
- Fraunhofer IAP Developing Contact lenses With Medicine and Sugarhttps://modernod.com/news/fraunhofer-iap-developing-contact-lenses-with-medicine-and-sugar/2476476/Researchers at the Fraunhofer Institute for Applied Polymer Research IAP are working with Israeli and German partners to develop long-wearing contact lenses that can release medicine. The active ingredient is encapsulated in liposomes and bound to the inside of the contact lenses. This enables it
- Ophthotech Changes Name to Iveric bio as it Transitions to Gene Therapy Companyhttps://modernod.com/news/ophthotech-changes-name-to-iveric-bio-as-it-transitions-to-gene-therapy-company/2476473/Ophthotech announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs) with unmet medical needs, the company
- Visioneering Technologies Creates Educational Series for Eye Care Practitionershttps://modernod.com/news/visioneering-technologies-creates-educational-series-for-eye-care-practitioners/2476471/Visioneering Technologies, maker of the NaturalVue Multifocal 1 Day contact lenses, announced the creation of a new educational series for eye care practitioners featuring some of the world’s leading researchers and clinicians, according to a company news release. The first installment of
- SilkTech Biopharmaceuticals’ IND Submission Cleared by FDA for Dry Eye Drophttps://modernod.com/news/silktech-biopharmaceuticals-ind-submission-cleared-by-fda-phase-2-clinical-trial-initiated-for-patients-with-dry-eye-disease/2476469/SilkTech Biopharmaceuticals announced the company has received clearance of its investigational new drug (IND) submission with the FDA for its SDP-4 eye drop product. In addition, the company has initiated a phase 2 clinical trial for its first-in-class drug to assess the safety and efficacy of t